Astra counts the cost of its Covid-19 vaccine
The link between Astrazeneca’s vaccine and blood clots strengthens, but forecasts show that it was never expected to generate huge sales.
Fibrogen stretches the bounds of credibility
Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
Drug rejections hold steady in 2020
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
Invitae borrows against the future
Cancer diagnosis is likely to see a huge resurgence in demand as the pandemic ebbs, and Invitae wants to be ready.
